Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
TUCSON, Ariz., May 01, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 first quarter results after market close on Monday, May 15, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Monday, May 15 to discuss these results and answer questions.
Individuals interested in listening to the conference call may do so by dialing (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers (conference ID: 13619211), or from the webcast on the “Investors” section of the Company’s website at: www.htgmolecular.com. The webcast will be available on the Company’s website for 90 days following the completion of the call.
About HTG:
Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: (415) 513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: (520) 547-2827 x130 Email: [email protected]
